{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T13:25:23Z","timestamp":1794144323817,"version":"4.8.0"},"reference-count":285,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41577-025-01229-3","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:21:56Z","timestamp":1760440916000},"page":"230-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Microenvironmental regulation of solid tumour resistance to CAR T cell therapy"],"prefix":"10.1038","volume":"26","author":[{"given":"Zachary L.","family":"Lamplugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Wellhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0241-3557","authenticated-orcid":false,"given":"Carl H.","family":"June","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6290-0595","authenticated-orcid":false,"given":"Yi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"1229_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41577-024-01111-8","volume":"25","author":"M Roerden","year":"2025","unstructured":"Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat. Rev. Immunol. 25, 353\u2013369 (2025).","journal-title":"Nat. Rev. Immunol."},{"key":"1229_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao, X. et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol. Cancer 20, 131 (2021).","journal-title":"Mol. Cancer"},{"key":"1229_CR3","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/cac2.12345","volume":"42","author":"K Cheng","year":"2022","unstructured":"Cheng, K. et al. Tumor-associated macrophages in liver cancer: from mechanisms to therapy. Cancer Commun. 42, 1112\u20131140 (2022).","journal-title":"Cancer Commun."},{"key":"1229_CR4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","volume":"19","author":"DJ Propper","year":"2022","unstructured":"Propper, D. J. & Balkwill, F. R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol. 19, 237\u2013253 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1229_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga, A. J., Chow, M. T. & Luster, A. D. Chemokines and the immune response to cancer. Immunity 54, 859\u2013874 (2021).","journal-title":"Immunity"},{"key":"1229_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","volume":"3","author":"G Bergers","year":"2003","unstructured":"Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401\u2013410 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"1229_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.trecan.2019.05.007","volume":"5","author":"Y Fan","year":"2019","unstructured":"Fan, Y. Vascular detransformation for cancer therapy. Trends Cancer 5, 460\u2013463 (2019).","journal-title":"Trends Cancer"},{"key":"1229_CR8","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"ZR Huinen","year":"2021","unstructured":"Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P. & Griffioen, A. W. Anti-angiogenic agents\u2014overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol. 18, 527\u2013540 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1229_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","volume":"2","author":"W Ma","year":"2021","unstructured":"Ma, W. et al. Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma. Nat. Cancer 2, 83\u201397 (2021).","journal-title":"Nat. Cancer"},{"key":"1229_CR10","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1172\/JCI84876","volume":"126","author":"M Huang","year":"2016","unstructured":"Huang, M. et al. c-Met-mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma. J. Clin. Invest. 126, 1801\u20131814 (2016).","journal-title":"J. Clin. Invest."},{"key":"1229_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05982-z","volume":"9","author":"T Liu","year":"2018","unstructured":"Liu, T. et al. PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma. Nat. Commun. 9, 3439 (2018).","journal-title":"Nat. Commun."},{"key":"1229_CR12","doi-asserted-by":"publisher","first-page":"eabm6388","DOI":"10.1126\/sciimmunol.abm6388","volume":"7","author":"EJM Huijbers","year":"2022","unstructured":"Huijbers, E. J. M., Khan, K. A., Kerbel, R. S. & Griffioen, A. W. Tumors resurrect an embryonic vascular program to escape immunity. Sci. Immunol. 7, eabm6388 (2022).","journal-title":"Sci. Immunol."},{"key":"1229_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03050-0","volume":"9","author":"Q Wang","year":"2018","unstructured":"Wang, Q. et al. Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2\u03b1. Nat. Commun. 9, 559 (2018).","journal-title":"Nat. Commun."},{"key":"1229_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00262-009-0747-y","volume":"59","author":"JK Mulligan","year":"2010","unstructured":"Mulligan, J. K. & Young, M. R. Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol. Immunother. 59, 267\u2013277 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"1229_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrd2115","volume":"6","author":"J Folkman","year":"2007","unstructured":"Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug. Discov. 6, 273\u2013286 (2007).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1229_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nature04478","volume":"438","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 438, 932\u2013936 (2005).","journal-title":"Nature"},{"key":"1229_CR17","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl Acad. Sci. USA 109, 17561\u201317566 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1229_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005583","volume":"11","author":"X Dong","year":"2023","unstructured":"Dong, X. et al. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice. J. Immunother. Cancer 11, e005583 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR19","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-09-3073","volume":"16","author":"SS Chae","year":"2010","unstructured":"Chae, S. S. et al. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin. Cancer Res. 16, 3618\u20133627 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR20","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ccell.2016.10.018","volume":"30","author":"JS Park","year":"2016","unstructured":"Park, J. S. et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell 30, 953\u2013967 (2016).","journal-title":"Cancer Cell"},{"key":"1229_CR21","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1172\/JCI93825","volume":"127","author":"J Kim","year":"2017","unstructured":"Kim, J. et al. YAP\/TAZ regulates sprouting angiogenesis and vascular barrier maturation. J. Clin. Invest. 127, 3441\u20133461 (2017).","journal-title":"J. Clin. Invest."},{"key":"1229_CR22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2219199120","volume":"120","author":"M Datta","year":"2023","unstructured":"Datta, M. et al. Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models. Proc. Natl Acad. Sci. USA 120, e2219199120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1229_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ccr.2014.06.025","volume":"26","author":"H Maes","year":"2014","unstructured":"Maes, H. et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 26, 190\u2013206 (2014).","journal-title":"Cancer Cell"},{"key":"1229_CR24","doi-asserted-by":"publisher","first-page":"eadn0904","DOI":"10.1126\/scitranslmed.adn0904","volume":"16","author":"Z Lu","year":"2024","unstructured":"Lu, Z. et al. Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. Sci. Transl. Med. 16, eadn0904 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1229_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.molmed.2023.11.002","volume":"30","author":"AH Cleveland","year":"2024","unstructured":"Cleveland, A. H. & Fan, Y. Reprogramming endothelial cells to empower cancer immunotherapy. Trends Mol. Med. 30, 126\u2013135 (2024).","journal-title":"Trends Mol. Med."},{"key":"1229_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cell.2013.06.037","volume":"154","author":"K De Bock","year":"2013","unstructured":"De Bock, K. et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 154, 651\u2013663 (2013).","journal-title":"Cell"},{"key":"1229_CR27","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","volume":"30","author":"AR Cantelmo","year":"2016","unstructured":"Cantelmo, A. R. et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell 30, 968\u2013985 (2016).","journal-title":"Cancer Cell"},{"key":"1229_CR28","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.apsb.2022.02.014","volume":"12","author":"Y Shan","year":"2022","unstructured":"Shan, Y. et al. Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment. Acta Pharm. Sin. B 12, 1825\u20131839 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"1229_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cmet.2023.01.010","volume":"35","author":"D Zhang","year":"2023","unstructured":"Zhang, D. et al. PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy. Cell Metab. 35, 517\u2013534.e8 (2023).","journal-title":"Cell Metab."},{"key":"1229_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature14362","volume":"520","author":"S Schoors","year":"2015","unstructured":"Schoors, S. et al. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature 520, 192\u2013197 (2015).","journal-title":"Nature"},{"key":"1229_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.trecan.2020.10.001","volume":"7","author":"S Milutinovic","year":"2021","unstructured":"Milutinovic, S., Abe, J., Godkin, A., Stein, J. V. & Gallimore, A. The dual role of high endothelial venules in cancer progression versus immunity. Trends Cancer 7, 214\u2013225 (2021).","journal-title":"Trends Cancer"},{"key":"1229_CR32","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","volume":"40","author":"Y Hua","year":"2022","unstructured":"Hua, Y. et al. Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. Cancer Cell 40, 1600\u20131618.e10 (2022).","journal-title":"Cancer Cell"},{"key":"1229_CR33","doi-asserted-by":"publisher","first-page":"eaak9679","DOI":"10.1126\/scitranslmed.aak9679","volume":"9","author":"E Allen","year":"2017","unstructured":"Allen, E. et al. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med. 9, eaak9679 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1229_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"Fang, W. et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA 332, 561\u2013570 (2024).","journal-title":"JAMA"},{"key":"1229_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","volume":"21","author":"TR Cox","year":"2021","unstructured":"Cox, T. R. The matrix in cancer. Nat. Rev. Cancer 21, 217\u2013238 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1229_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.it.2024.07.009","volume":"45","author":"Y Cho","year":"2024","unstructured":"Cho, Y. & Doh, J. The extracellular matrix in solid tumor immunotherapy. Trends Immunol. 45, 705\u2013714 (2024).","journal-title":"Trends Immunol."},{"key":"1229_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ceb.2009.05.003","volume":"21","author":"T L\u00e4mmermann","year":"2009","unstructured":"L\u00e4mmermann, T. & Sixt, M. Mechanical modes of \u2018amoeboid\u2019 cell migration. Curr. Opin. Cell Biol. 21, 636\u2013644 (2009).","journal-title":"Curr. Opin. Cell Biol."},{"key":"1229_CR38","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1182\/blood-2002-12-3791","volume":"102","author":"K Wolf","year":"2003","unstructured":"Wolf, K., M\u00fcller, R., Borgmann, S., Br\u00f6cker, E. B. & Friedl, P. Amoeboid shape change and contact guidance: T-lymphocyte crawling through fibrillar collagen is independent of matrix remodeling by MMPs and other proteases. Blood 102, 3262\u20133269 (2003).","journal-title":"Blood"},{"key":"1229_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18298-8","volume":"11","author":"DH Peng","year":"2020","unstructured":"Peng, D. H. et al. Collagen promotes anti-PD-1\/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nat. Commun. 11, 4520 (2020).","journal-title":"Nat. Commun."},{"key":"1229_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","volume":"574","author":"RJ Johnston","year":"2019","unstructured":"Johnston, R. J. et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature 574, 565\u2013570 (2019).","journal-title":"Nature"},{"key":"1229_CR41","doi-asserted-by":"publisher","first-page":"jcs242883","DOI":"10.1242\/jcs.242883","volume":"16","author":"X Luo","year":"2020","unstructured":"Luo, X. et al. Lymphocytes perform reverse adhesive haptotaxis mediated by LFA-1 integrins. J. Cell. Sci. 16, jcs242883 (2020).","journal-title":"J. Cell. Sci."},{"key":"1229_CR42","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/JCI45817","volume":"122","author":"H Salmon","year":"2012","unstructured":"Salmon, H. et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122, 899\u2013910 (2012).","journal-title":"J. Clin. Invest."},{"key":"1229_CR43","doi-asserted-by":"publisher","first-page":"25792","DOI":"10.1074\/jbc.M113.479584","volume":"288","author":"H He","year":"2013","unstructured":"He, H., Zhang, S., Tighe, S., Son, J. & Tseng, S. C. G. Immobilized heavy chain-hyaluronic acid polarizes lipopolysaccharide-activated macrophages toward M2 phenotype. J. Biol. Chem. 288, 25792\u201325803 (2013).","journal-title":"J. Biol. Chem."},{"key":"1229_CR44","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.4049\/jimmunol.1900789","volume":"205","author":"AMH Larsen","year":"2020","unstructured":"Larsen, A. M. H. et al. Collagen density modulates the immunosuppressive functions of macrophages. J. Immunol. 205, 1461\u20131472 (2020).","journal-title":"J. Immunol."},{"key":"1229_CR45","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s43018-022-00353-6","volume":"3","author":"T Hongu","year":"2022","unstructured":"Hongu, T. et al. Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs. Nat. Cancer 3, 486\u2013504 (2022).","journal-title":"Nat. Cancer"},{"key":"1229_CR46","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/JCO.2001.19.15.3447","volume":"19","author":"SR Bramhall","year":"2001","unstructured":"Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C. & Buckels, J. A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. 19, 3447\u20133455 (2001).","journal-title":"J. Clin. Oncol."},{"key":"1229_CR47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.bjc.6600446","volume":"87","author":"SR Bramhall","year":"2002","unstructured":"Bramhall, S. R. et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87, 161\u2013167 (2002).","journal-title":"Br. J. Cancer"},{"key":"1229_CR48","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1158\/1078-0432.CCR-04-2144","volume":"11","author":"JR Goffin","year":"2005","unstructured":"Goffin, J. R. et al. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin. Cancer Res. 11, 3417\u20133424 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR49","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1200\/JCO.2003.02.098","volume":"21","author":"MJ Moore","year":"2003","unstructured":"Moore, M. J. et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3296\u20133302 (2003).","journal-title":"J. Clin. Oncol."},{"key":"1229_CR50","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","volume":"36","author":"SR Hingorani","year":"2018","unstructured":"Hingorani, S. R. et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol. 36, 359\u2013366 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1229_CR51","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/0008-5472.CAN-05-2242","volume":"66","author":"TD McKee","year":"2006","unstructured":"McKee, T. D. et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 66, 2509\u20132513 (2006).","journal-title":"Cancer Res."},{"key":"1229_CR52","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.15252\/emmm.201404827","volume":"7","author":"BW Miller","year":"2015","unstructured":"Miller, B. W. et al. Targeting the LOX\/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy. EMBO Mol. Med. 7, 1063\u20131076 (2015).","journal-title":"EMBO Mol. Med."},{"key":"1229_CR53","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.58688","volume":"10","author":"A Nicolas-Boluda","year":"2021","unstructured":"Nicolas-Boluda, A. et al. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. eLife 10, e58688 (2021).","journal-title":"eLife"},{"key":"1229_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006720","volume":"11","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer. J. Immunother. Cancer 11, e006720 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR55","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","volume":"21","author":"I Caruana","year":"2015","unstructured":"Caruana, I. et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nat. Med. 21, 524\u2013529 (2015).","journal-title":"Nat. Med."},{"key":"1229_CR56","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/s41423-024-01228-9","volume":"21","author":"R Zheng","year":"2024","unstructured":"Zheng, R. et al. Specific ECM degradation potentiates the antitumor activity of CAR-T cells in solid tumors. Cell Mol. Immunol. 21, 1491\u20131504 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"1229_CR57","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41568-022-00505-x","volume":"22","author":"GM Allen","year":"2022","unstructured":"Allen, G. M. & Lim, W. A. Rethinking cancer targeting strategies in the era of smart cell therapeutics. Nat. Rev. Cancer 22, 693\u2013702 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"1229_CR58","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","volume":"13","author":"M Hamieh","year":"2023","unstructured":"Hamieh, M., Mansilla-Soto, J., Rivi\u00e8re, I. & Sadelain, M. Programming CAR T cell tumor recognition: tuned antigen sensing and logic gating. Cancer Discov. 13, 829\u2013843 (2023).","journal-title":"Cancer Discov."},{"key":"1229_CR59","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0168-8278(97)80186-9","volume":"27","author":"M Pines","year":"1997","unstructured":"Pines, M., Knopov, V., Genina, O., Lavelin, I. & Nagler, A. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol. 27, 391\u2013398 (1997).","journal-title":"J. Hepatol."},{"key":"1229_CR60","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/MPA.0b013e3181967670","volume":"38","author":"O Zion","year":"2009","unstructured":"Zion, O. et al. Inhibition of transforming growth factor \u03b2 signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 38, 427\u2013435 (2009).","journal-title":"Pancreas"},{"key":"1229_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00262-020-02666-w","volume":"70","author":"K Premkumar","year":"2021","unstructured":"Premkumar, K. & Shankar, B. S. TGF-\u03b2R inhibitor SB431542 restores immune suppression induced by regulatory B\u2013T cell axis and decreases tumour burden in murine fibrosarcoma. Cancer Immunol. Immunother. 70, 153\u2013168 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"1229_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090353","volume":"9","author":"JC Morris","year":"2014","unstructured":"Morris, J. C. et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-\u03b2 (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 9, e90353 (2014).","journal-title":"PLoS One"},{"key":"1229_CR63","doi-asserted-by":"publisher","first-page":"82889","DOI":"10.18632\/oncotarget.12658","volume":"7","author":"K Takai","year":"2016","unstructured":"Takai, K., Le, A., Weaver, V. M. & Werb, Z. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7, 82889\u201382901 (2016).","journal-title":"Oncotarget"},{"key":"1229_CR64","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346\u2013354 (2013).","journal-title":"Nature"},{"key":"1229_CR65","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1158\/0008-5472.CAN-12-3180","volume":"73","author":"S Kozono","year":"2013","unstructured":"Kozono, S. et al. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells. Cancer Res. 73, 2345\u20132356 (2013).","journal-title":"Cancer Res."},{"key":"1229_CR66","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1053\/j.gastro.2011.06.047","volume":"141","author":"FE Froeling","year":"2011","unstructured":"Froeling, F. E. et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-\u03b2-catenin signaling to slow tumor progression. Gastroenterology 141, 1486\u20131497.e1\u2013e14 (2011).","journal-title":"Gastroenterology"},{"key":"1229_CR67","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1158\/2159-8290.CD-20-1484","volume":"12","author":"KM McAndrews","year":"2022","unstructured":"McAndrews, K. M. et al. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer Discov. 12, 1580\u20131597 (2022).","journal-title":"Cancer Discov."},{"key":"1229_CR68","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran, E. et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210, 1125\u20131135 (2013).","journal-title":"J. Exp. Med."},{"key":"1229_CR69","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang, L. C. et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2, 154\u2013166 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"1229_CR70","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu, G., Rui, W., Zhao, X. & Lin, X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol. Immunol. 18, 1085\u20131095 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"1229_CR71","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty, G. L. et al. Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155, 29\u201332 (2018).","journal-title":"Gastroenterology"},{"key":"1229_CR72","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 31, 2309\u20132325 (2023).","journal-title":"Mol. Ther."},{"key":"1229_CR73","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356\u2013371 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1229_CR74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser, S. A., Ozbay Kurt, F. G., Arkhypov, I., Utikal, J. & Umansky, V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat. Rev. Clin. Oncol. 21, 147\u2013164 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1229_CR75","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ccell.2024.04.002","volume":"42","author":"C Bl\u00e9riot","year":"2024","unstructured":"Bl\u00e9riot, C., Dunsmore, G., Alonso-Curbelo, D. & Ginhoux, F. A temporal perspective for tumor-associated macrophage identities and functions. Cancer Cell 42, 747\u2013758 (2024).","journal-title":"Cancer Cell"},{"key":"1229_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361 (2014).","journal-title":"Immunity"},{"key":"1229_CR77","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta, L. & Pollard, J. W. Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug. Discov. 17, 887\u2013904 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1229_CR78","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3390\/cancers13081850","volume":"13","author":"J Cinier","year":"2021","unstructured":"Cinier, J. et al. Recruitment and expansion of Tregs cells in the tumor environment \u2014 how to target them? Cancers (Basel) 13, 1850 (2021).","journal-title":"Cancers (Basel)"},{"key":"1229_CR79","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1084\/jem.20050463","volume":"202","author":"F Ghiringhelli","year":"2005","unstructured":"Ghiringhelli, F. et al. Tumor cells convert immature myeloid dendritic cells into TGF-\u03b2-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202, 919\u2013929 (2005).","journal-title":"J. Exp. Med."},{"key":"1229_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li, C., Jiang, P., Wei, S., Xu, X. & Wang, J. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol. Cancer 19, 116 (2020).","journal-title":"Mol. Cancer"},{"key":"1229_CR81","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson, M. J. et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591, 645\u2013651 (2021).","journal-title":"Nature"},{"key":"1229_CR82","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162\u2013174 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1229_CR83","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 19, 108\u2013119 (2018).","journal-title":"Nat. Immunol."},{"key":"1229_CR84","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","volume":"181","author":"JI Youn","year":"2008","unstructured":"Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791\u20135802 (2008).","journal-title":"J. Immunol."},{"key":"1229_CR85","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"1229_CR86","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485\u2013498 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1229_CR87","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka, A. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res. 27, 109\u2013118 (2017).","journal-title":"Cell Res."},{"key":"1229_CR88","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/bjd.18379","volume":"182","author":"T Gambichler","year":"2020","unstructured":"Gambichler, T. et al. Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade. Br. J. Dermatol. 182, 1214\u20131220 (2020).","journal-title":"Br. J. Dermatol."},{"key":"1229_CR89","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell, J. et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 31, 2181\u20132190 (2017).","journal-title":"Leukemia"},{"key":"1229_CR90","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3324\/haematol.2023.283758","volume":"109","author":"M Casey","year":"2024","unstructured":"Casey, M. et al. Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy. Haematologica 109, 787\u2013798 (2024).","journal-title":"Haematologica"},{"key":"1229_CR91","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler, N. et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat. Med. 28, 1872\u20131882 (2022).","journal-title":"Nat. Med."},{"key":"1229_CR92","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","volume":"28","author":"Z Good","year":"2022","unstructured":"Good, Z. et al. Post-infusion CAR Treg cells identify patients resistant to CD19-CAR therapy. Nat. Med. 28, 1860\u20131871 (2022).","journal-title":"Nat. Med."},{"key":"1229_CR93","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"1229_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000764","volume":"8","author":"LA Marshall","year":"2020","unstructured":"Marshall, L. A. et al. Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4. J. Immunother. Cancer 8, e000764 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR95","doi-asserted-by":"publisher","first-page":"6190","DOI":"10.1021\/acs.jmedchem.9b00506","volume":"62","author":"JJ Jackson","year":"2019","unstructured":"Jackson, J. J. et al. Discovery of a potent and selective CCR4 antagonist that inhibits Treg trafficking into the tumor microenvironment. J. Med. Chem. 62, 6190\u20136213 (2019).","journal-title":"J. Med. Chem."},{"key":"1229_CR96","doi-asserted-by":"crossref","unstructured":"Kim, T. M. et al. Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor. J. Immunother. Cancer 11 (Suppl. 2), Abstract 629-C (2023).","DOI":"10.1136\/jitc-2023-SITC2023.0629-C"},{"key":"1229_CR97","doi-asserted-by":"publisher","first-page":"CT226","DOI":"10.1158\/1538-7445.AM2024-CT226","volume":"84","author":"J Muzaffar","year":"2024","unstructured":"Muzaffar, J. et al. Abstract CT226: phase 2 study of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) previously treated with checkpoint inhibitor. Cancer Res. 84, CT226 (2024).","journal-title":"Cancer Res."},{"key":"1229_CR98","doi-asserted-by":"publisher","first-page":"6833","DOI":"10.4049\/jimmunol.0904084","volume":"184","author":"DB Hoelzinger","year":"2010","unstructured":"Hoelzinger, D. B. et al. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J. Immunol. 184, 6833\u20136842 (2010).","journal-title":"J. Immunol."},{"key":"1229_CR99","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1158\/0008-5472.CAN-18-1119","volume":"78","author":"DO Villarreal","year":"2018","unstructured":"Villarreal, D. O. et al. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. Cancer Res. 78, 5340\u20135348 (2018).","journal-title":"Cancer Res."},{"key":"1229_CR100","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.3390\/biomedicines11112910","volume":"11","author":"N Kim","year":"2023","unstructured":"Kim, N. et al. CCR8 as a therapeutic novel target: omics-integrated comprehensive analysis for systematically prioritizing indications. Biomedicines 11, 2910 (2023).","journal-title":"Biomedicines"},{"key":"1229_CR101","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10238-024-01362-8","volume":"24","author":"HG Roider","year":"2024","unstructured":"Roider, H. G. et al. Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody. Clin. Exp. Med. 24, 122 (2024).","journal-title":"Clin. Exp. Med."},{"key":"1229_CR102","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20240445","volume":"222","author":"SN Tan","year":"2025","unstructured":"Tan, S. N. et al. Regulatory T cells converted from TH1 cells in tumors suppress cancer immunity via CD39. J. Exp. Med. 222, e20240445(2025).","journal-title":"J. Exp. Med."},{"key":"1229_CR103","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.4049\/jimmunol.163.10.5211","volume":"163","author":"J Shimizu","year":"1999","unstructured":"Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211\u20135218 (1999).","journal-title":"J. Immunol."},{"key":"1229_CR104","first-page":"3128","volume":"59","author":"S Onizuka","year":"1999","unstructured":"Onizuka, S. et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor \u03b1) monoclonal antibody. Cancer Res. 59, 3128\u20133133 (1999).","journal-title":"Cancer Res."},{"key":"1229_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000860","volume":"8","author":"F Zammarchi","year":"2020","unstructured":"Zammarchi, F. et al. CD25-targeted antibody\u2013drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J. Immunother. Cancer 8, e000860 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR106","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.4049\/jimmunol.179.7.4919","volume":"179","author":"DJ Powell Jr.","year":"2007","unstructured":"Powell, D. J. Jr. et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J. Immunol. 179, 4919\u20134928 (2007).","journal-title":"J. Immunol."},{"key":"1229_CR107","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1073\/pnas.1820388116","volume":"116","author":"M Onda","year":"2019","unstructured":"Onda, M., Kobayashi, K. & Pastan, I. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. Proc. Natl Acad. Sci. USA 116, 4575\u20134582 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1229_CR108","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1158\/2326-6066.CIR-13-0013","volume":"1","author":"MJ Selby","year":"2013","unstructured":"Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32\u201342 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"1229_CR109","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/eji.201847659","volume":"49","author":"A Tanaka","year":"2019","unstructured":"Tanaka, A. & Sakaguchi, S. Targeting Treg cells in cancer immunotherapy. Eur. J. Immunol. 49, 1140\u20131146 (2019).","journal-title":"Eur. J. Immunol."},{"key":"1229_CR110","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1073\/pnas.1812186116","volume":"116","author":"D Ha","year":"2019","unstructured":"Ha, D. et al. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. Proc. Natl Acad. Sci. USA 116, 609\u2013618 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1229_CR111","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","volume":"46","author":"F Arce Vargas","year":"2017","unstructured":"Arce Vargas, F. et al. Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46, 577\u2013586 (2017).","journal-title":"Immunity"},{"key":"1229_CR112","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s43018-020-00133-0","volume":"1","author":"I Solomon","year":"2020","unstructured":"Solomon, I. et al. CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nat. Cancer 1, 1153\u20131166 (2020).","journal-title":"Nat. Cancer"},{"key":"1229_CR113","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41590-024-01746-8","volume":"25","author":"X Long","year":"2024","unstructured":"Long, X. et al. Targeting JMJD1C to selectively disrupt tumor Treg cell fitness enhances antitumor immunity. Nat. Immunol. 25, 525\u2013536 (2024).","journal-title":"Nat. Immunol."},{"key":"1229_CR114","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191009","volume":"217","author":"A Tanaka","year":"2020","unstructured":"Tanaka, A. et al. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. J. Exp. Med. 217, e20191009 (2020).","journal-title":"J. Exp. Med."},{"key":"1229_CR115","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/febs.17326","volume":"292","author":"Y Sun","year":"2024","unstructured":"Sun, Y. et al. Depletion of Tregs from CD4+ CAR-T cells enhances the tumoricidal effect of CD8+ CAR-T cells in anti-CD19 CAR-T therapy. FEBS J. 292, 1904\u20131919\u00a0(2024).","journal-title":"FEBS J."},{"key":"1229_CR116","doi-asserted-by":"publisher","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","volume":"15","author":"N Wellhausen","year":"2023","unstructured":"Wellhausen, N. et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci. Transl. Med. 15, eadi1145 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1229_CR117","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41568-024-00723-5","volume":"24","author":"N Wellhausen","year":"2024","unstructured":"Wellhausen, N., Baek, J., Gill, S. I. & June, C. H. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance. Nat. Rev. Can. 24, 614\u2013628 (2024).","journal-title":"Nat. Rev. Can."},{"key":"1229_CR118","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41591-024-03282-2","volume":"31","author":"J Pan","year":"2025","unstructured":"Pan, J. et al. Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a phase 1 trial. Nat. Med. 31, 126\u2013136 (2025).","journal-title":"Nat. Med."},{"key":"1229_CR119","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","volume":"30","author":"BLZ Oh","year":"2024","unstructured":"Oh, B. L. Z. et al. Fratricide-resistant CD7-CAR T cells in T-ALL. Nat. Med. 30, 3687\u20133696 (2024).","journal-title":"Nat. Med."},{"key":"1229_CR120","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/biomedicines9020197","volume":"9","author":"T Lozano","year":"2021","unstructured":"Lozano, T. et al. Searching for peptide inhibitors of T regulatory cell activity by targeting specific domains of FOXP3 transcription factor. Biomedicines 9, 197 (2021).","journal-title":"Biomedicines"},{"key":"1229_CR121","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.omtn.2021.05.005","volume":"25","author":"AJ Manrique-Rinc\u00f3n","year":"2021","unstructured":"Manrique-Rinc\u00f3n, A. J. et al. Aptamer-mediated transcriptional gene silencing of Fox p 3 inhibits regulatory T cells and potentiates antitumor response. Mol. Ther. Nucleic Acids 25, 143\u2013151 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1229_CR122","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/mt.2011.9","volume":"19","author":"DM Kofler","year":"2011","unstructured":"Kofler, D. M. et al. CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Mol. Ther. 19, 760\u2013767 (2011).","journal-title":"Mol. Ther."},{"key":"1229_CR123","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1158\/1078-0432.CCR-18-1211","volume":"25","author":"CM Suryadevara","year":"2019","unstructured":"Suryadevara, C. M. et al. Preventing Lck activation in CAR T cells confers Treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in nonlymphodepleted hosts. Clin. Cancer Res. 25, 358\u2013368 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR124","doi-asserted-by":"publisher","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","volume":"13","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Sci. Transl. Med. 13, eabg6986 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1229_CR125","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.ymthe.2018.07.005","volume":"26","author":"V Golumba-Nagy","year":"2018","unstructured":"Golumba-Nagy, V., Kuehle, J., Hombach, A. A. & Abken, H. CD28-\u03b6 CAR T cells resist TGF-\u03b2 repression through IL-2 signaling, which can be mimicked by an engineered IL-7 autocrine loop. Mol. Ther. 26, 2218\u20132230 (2018).","journal-title":"Mol. Ther."},{"key":"1229_CR126","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365 (2022).","journal-title":"Nature"},{"key":"1229_CR127","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-024-01641-7","volume":"17","author":"M Pezzella","year":"2024","unstructured":"Pezzella, M. et al. Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells. J. Hematol. Oncol. 17, 127 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1229_CR128","doi-asserted-by":"publisher","first-page":"7163","DOI":"10.1182\/blood-2024-210218","volume":"144","author":"J Zhu","year":"2024","unstructured":"Zhu, J. et al. Elevated CD10\u2013 G-MDSC-like neutrophils correlate with non-response and poor prognosis of CD19 CAR T-cell therapy for B-cell acute lymphoblastic leukemia. Blood 144, 7163 (2024).","journal-title":"Blood"},{"key":"1229_CR129","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1182\/blood-2023-186478","volume":"142","author":"E Galli","year":"2023","unstructured":"Galli, E. et al. High levels of circulating granulocytic myeloid-derived suppressor cells (G-MDSCs) predict failure of CD19-targeting CAR-T cell therapy. Blood 142, 1015 (2023).","journal-title":"Blood"},{"key":"1229_CR130","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.3390\/cancers13246293","volume":"13","author":"K Bullock","year":"2021","unstructured":"Bullock, K. & Richmond, A. Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy. Cancers (Basel) 13, 6293 (2021).","journal-title":"Cancers (Basel)"},{"key":"1229_CR131","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.7150\/jca.61567","volume":"12","author":"Y Dang","year":"2021","unstructured":"Dang, Y. et al. GOLM1 drives colorectal cancer metastasis by regulating myeloid-derived suppressor cells. J. Cancer 12, 7158\u20137166 (2021).","journal-title":"J. Cancer"},{"key":"1229_CR132","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1073\/pnas.1910856117","volume":"117","author":"JA Flores-Toro","year":"2020","unstructured":"Flores-Toro, J. A. et al. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc. Natl Acad. Sci. USA 117, 1129\u20131138 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1229_CR133","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/08923973.2017.1417997","volume":"40","author":"L Yang","year":"2018","unstructured":"Yang, L. et al. Blockade of CCR5-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy in gastric cancer. Immunopharmacol. Immunotoxicol. 40, 91\u201397 (2018).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"1229_CR134","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41586-020-2054-x","volume":"579","author":"Z Lu","year":"2020","unstructured":"Lu, Z. et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature 579, 284\u2013290 (2020).","journal-title":"Nature"},{"key":"1229_CR135","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.ymthe.2023.04.008","volume":"31","author":"B Zhang","year":"2023","unstructured":"Zhang, B. et al. Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy. Mol. Ther. 31, 2105\u20132119 (2023).","journal-title":"Mol. Ther."},{"key":"1229_CR136","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ymthe.2020.09.034","volume":"29","author":"R Sun","year":"2021","unstructured":"Sun, R. et al. Olaparib suppresses MDSC recruitment via SDF1\u03b1\/CXCR4 axis to improve the anti-tumor efficacy of CAR-T cells on breast cancer in mice. Mol. Ther. 29, 60\u201374 (2021).","journal-title":"Mol. Ther."},{"key":"1229_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao, Z. et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat. Commun. 14, 5110 (2023).","journal-title":"Nat. Commun."},{"key":"1229_CR138","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","volume":"70","author":"J Vincent","year":"2010","unstructured":"Vincent, J. et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052\u20133061 (2010).","journal-title":"Cancer Res."},{"key":"1229_CR139","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.1158\/1078-0432.CCR-05-0883","volume":"11","author":"E Suzuki","year":"2005","unstructured":"Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. & Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+\/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713\u20136721 (2005).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR140","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s12026-015-8734-1","volume":"64","author":"X Huang","year":"2016","unstructured":"Huang, X., Cui, S. & Shu, Y. Cisplatin selectively downregulated the frequency and immunoinhibitory function of myeloid-derived suppressor cells in a murine B16 melanoma model. Immunol. Res. 64, 160\u2013170 (2016).","journal-title":"Immunol. Res."},{"key":"1229_CR141","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.molimm.2012.10.035","volume":"54","author":"Y Zheng","year":"2013","unstructured":"Zheng, Y. et al. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol. Immunol. 54, 74\u201383 (2013).","journal-title":"Mol. Immunol."},{"key":"1229_CR142","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1151591","volume":"5","author":"A Vila-Leahey","year":"2016","unstructured":"Vila-Leahey, A. et al. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology 5, e1151591 (2016).","journal-title":"Oncoimmunology"},{"key":"1229_CR143","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ebiom.2019.08.025","volume":"47","author":"L Fultang","year":"2019","unstructured":"Fultang, L. et al. MDSC targeting with gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine 47, 235\u2013246 (2019).","journal-title":"EBioMedicine"},{"key":"1229_CR144","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1158\/1078-0432.CCR-16-1784","volume":"23","author":"GA Dominguez","year":"2017","unstructured":"Dominguez, G. A. et al. Selective targeting of myeloid-derived suppressor cells in cancer patients using DS-8273a, an agonistic TRAIL-R2 antibody. Clin. Cancer Res. 23, 2942\u20132950 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR145","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003237","volume":"9","author":"SA Nalawade","year":"2021","unstructured":"Nalawade, S. A. et al. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J. Immunother. Cancer 9, e003237 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR146","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar, R. et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer Immunol. Res. 7, 363\u2013375 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1229_CR147","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/CJI.0000000000000301","volume":"43","author":"H Li","year":"2020","unstructured":"Li, H. et al. CAIX-specific CAR-T cells and sunitinib show synergistic effects against metastatic renal cancer models. J. Immunother. 43, 16\u201328 (2020).","journal-title":"J. Immunother."},{"key":"1229_CR148","doi-asserted-by":"publisher","first-page":"105829","DOI":"10.1016\/j.phrs.2021.105829","volume":"174","author":"M Lu","year":"2021","unstructured":"Lu, M. et al. Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer. Pharmacol. Res. 174, 105829 (2021).","journal-title":"Pharmacol. Res."},{"key":"1229_CR149","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini, P. et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203, 2691\u20132702 (2006).","journal-title":"J. Exp. Med."},{"key":"1229_CR150","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-09-3272","volume":"16","author":"S Nagaraj","year":"2010","unstructured":"Nagaraj, S. et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin. Cancer Res. 16, 1812\u20131823 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR151","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-15-0036","volume":"3","author":"F Hossain","year":"2015","unstructured":"Hossain, F. et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res. 3, 1236\u20131247 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"1229_CR152","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-019-1118-2","volume":"569","author":"F Veglia","year":"2019","unstructured":"Veglia, F. et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 569, 73\u201378 (2019).","journal-title":"Nature"},{"key":"1229_CR153","doi-asserted-by":"publisher","first-page":"11021","DOI":"10.1158\/0008-5472.CAN-07-2593","volume":"67","author":"Y Nefedova","year":"2007","unstructured":"Nefedova, Y. et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res. 67, 11021\u201311028 (2007).","journal-title":"Cancer Res."},{"key":"1229_CR154","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.1158\/0008-5472.CAN-06-1690","volume":"66","author":"N Mirza","year":"2006","unstructured":"Mirza, N. et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299\u20139307 (2006).","journal-title":"Cancer Res."},{"key":"1229_CR155","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1158\/1078-0432.CCR-22-2495","volume":"29","author":"RP Tobin","year":"2023","unstructured":"Tobin, R. P. et al. Targeting MDSC differentiation using ATRA: a phase I\/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma. Clin. Cancer Res. 29, 1209\u20131219 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR156","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","volume":"4","author":"AH Long","year":"2016","unstructured":"Long, A. H. et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4, 869\u2013880 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"1229_CR157","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/blood-2024-202659","volume":"144","author":"BF Frost","year":"2024","unstructured":"Frost, B. F. et al. BTK inhibition prevents the induction of myeloid-derived suppressor cells in malignancy and improves CART function. Blood 144, 909 (2024).","journal-title":"Blood"},{"key":"1229_CR158","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13115","volume":"54","author":"M Xu","year":"2021","unstructured":"Xu, M., Wang, Y., Xia, R., Wei, Y. & Wei, X. Role of the CCL2\u2013CCR2 signalling axis in cancer: mechanisms and therapeutic targeting. Cell Prolif. 54, e13115 (2021).","journal-title":"Cell Prolif."},{"key":"1229_CR159","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman, D. J. & Akkari, L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell 186, 1627\u20131651 (2023).","journal-title":"Cell"},{"key":"1229_CR160","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","volume":"22","author":"MC Takenaka","year":"2019","unstructured":"Takenaka, M. C. et al. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat. Neurosci. 22, 729\u2013740 (2019).","journal-title":"Nat. Neurosci."},{"key":"1229_CR161","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","volume":"66","author":"X Li","year":"2017","unstructured":"Li, X. et al. Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut 66, 157\u2013167 (2017).","journal-title":"Gut"},{"key":"1229_CR162","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007603","volume":"33","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. mRNA delivery of a bispecific single-domain antibody to polarize tumor-associated macrophages and synergize immunotherapy against liver malignancies. Adv. Mater. 33, e2007603 (2021).","journal-title":"Adv. Mater."},{"key":"1229_CR163","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264\u20131272 (2013).","journal-title":"Nat. Med."},{"key":"1229_CR164","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski, N. et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 18, 557\u2013564 (2016).","journal-title":"Neuro Oncol."},{"key":"1229_CR165","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1158\/1078-0432.CCR-21-1779","volume":"27","author":"GA Manji","year":"2021","unstructured":"Manji, G. A. et al. A phase I study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable sarcoma and malignant peripheral nerve sheath tumors. Clin. Cancer Res. 27, 5519\u20135527 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR166","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/neuonc\/noab228","volume":"24","author":"R Rao","year":"2022","unstructured":"Rao, R. et al. Glioblastoma genetic drivers dictate the function of tumor-associated macrophages\/microglia and responses to CSF1R inhibition. Neuro Oncol. 24, 584\u2013597 (2022).","journal-title":"Neuro Oncol."},{"key":"1229_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-20893-2","volume":"12","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia, A. et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat. Commun. 12, 877 (2021).","journal-title":"Nat. Commun."},{"key":"1229_CR168","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1158\/2326-6066.CIR-21-1075","volume":"10","author":"AR S\u00e1nchez-Paulete","year":"2022","unstructured":"S\u00e1nchez-Paulete, A. R. et al. Targeting macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity. Cancer Immunol. Res. 10, 1354\u20131369 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1229_CR169","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s40425-019-0807-6","volume":"7","author":"EM Scott","year":"2019","unstructured":"Scott, E. M. et al. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. J. Immunother. Cancer 7, 320 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR170","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612\u20131616 (2011).","journal-title":"Science"},{"key":"1229_CR171","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/2326-6066.CIR-18-0448","volume":"7","author":"IM Stromnes","year":"2019","unstructured":"Stromnes, I. M. et al. Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma. Cancer Immunol. Res. 7, 977\u2013989 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"1229_CR172","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","volume":"3","author":"R Winograd","year":"2015","unstructured":"Winograd, R. et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma. Cancer Immunol. Res. 3, 399\u2013411 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"1229_CR173","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.copbio.2019.01.010","volume":"60","author":"Q Zeng","year":"2019","unstructured":"Zeng, Q. & Jewell, C. M. Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy. Curr. Opin. Biotechnol. 60, 138\u2013145 (2019).","journal-title":"Curr. Opin. Biotechnol."},{"key":"1229_CR174","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","volume":"2","author":"CB Rodell","year":"2018","unstructured":"Rodell, C. B. et al. TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat. Biomed. Eng. 2, 578\u2013588 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"1229_CR175","doi-asserted-by":"publisher","first-page":"aad3018","DOI":"10.1126\/science.aad3018","volume":"352","author":"DF Quail","year":"2016","unstructured":"Quail, D. F. et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018 (2016).","journal-title":"Science"},{"key":"1229_CR176","doi-asserted-by":"publisher","first-page":"eabl7882","DOI":"10.1126\/sciadv.abl7882","volume":"8","author":"AR Poh","year":"2022","unstructured":"Poh, A. R. et al. Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy. Sci. Adv. 8, eabl7882 (2022).","journal-title":"Sci. Adv."},{"key":"1229_CR177","doi-asserted-by":"publisher","first-page":"eabq3558","DOI":"10.1126\/scitranslmed.abq3558","volume":"15","author":"F Yang","year":"2023","unstructured":"Yang, F. et al. Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy. Sci. Transl. Med. 15, eabq3558 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1229_CR178","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","volume":"630","author":"SA Yamada-Hunter","year":"2024","unstructured":"Yamada-Hunter, S. A. et al. Engineered CD47 protects T cells for enhanced antitumour immunity. Nature 630, 457\u2013465 (2024).","journal-title":"Nature"},{"key":"1229_CR179","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood.2022016101","volume":"141","author":"MM Dacek","year":"2023","unstructured":"Dacek, M. M. et al. Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRP\u03b1 checkpoint blocker. Blood 141, 2003\u20132015 (2023).","journal-title":"Blood"},{"key":"1229_CR180","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/intimm\/dxad033","volume":"36","author":"Y Kagoya","year":"2024","unstructured":"Kagoya, Y. Cytokine signaling in chimeric antigen receptor T-cell therapy. Int. Immunol. 36, 49\u201356 (2024).","journal-title":"Int. Immunol."},{"key":"1229_CR181","doi-asserted-by":"publisher","first-page":"684642","DOI":"10.3389\/fimmu.2021.684642","volume":"12","author":"M Bell","year":"2021","unstructured":"Bell, M. & Gottschalk, S. Engineered cytokine signaling to improve CAR T cell effector function. Front. Immunol. 12, 684642 (2021).","journal-title":"Front. Immunol."},{"key":"1229_CR182","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda, J. et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N. Engl. J. Med. 392, 1824\u20131835 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1229_CR183","doi-asserted-by":"publisher","first-page":"eabi5781","DOI":"10.1126\/sciadv.abi5781","volume":"7","author":"BL Cadilha","year":"2021","unstructured":"Cadilha, B. L. et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci. Adv. 7, eabi5781 (2021).","journal-title":"Sci. Adv."},{"key":"1229_CR184","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"1229_CR185","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724\u2013734 (2022).","journal-title":"Nat. Med."},{"key":"1229_CR186","doi-asserted-by":"publisher","first-page":"8706","DOI":"10.3390\/ijms22168706","volume":"22","author":"KE Noh","year":"2021","unstructured":"Noh, K. E. et al. TGF-\u03b2\/IL-7 chimeric switch receptor-expressing CAR-T cells inhibit recurrence of CD19-positive B cell lymphoma. Int. J. Mol. Sci. 22, 8706 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1229_CR187","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cell.2020.03.039","volume":"181","author":"TL Roth","year":"2020","unstructured":"Roth, T. L. et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell 181, 728\u2013744.e21 (2020).","journal-title":"Cell"},{"key":"1229_CR188","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","volume":"25","author":"S Mohammed","year":"2017","unstructured":"Mohammed, S. et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol. Ther. 25, 249\u2013258 (2017).","journal-title":"Mol. Ther."},{"key":"1229_CR189","doi-asserted-by":"publisher","first-page":"25538","DOI":"10.1074\/jbc.M110.127951","volume":"285","author":"S Wilkie","year":"2010","unstructured":"Wilkie, S. et al. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J. Biol. Chem. 285, 25538\u201325544 (2010).","journal-title":"J. Biol. Chem."},{"key":"1229_CR190","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","volume":"5","author":"N Tang","year":"2020","unstructured":"Tang, N. et al. TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 5, e133977 (2020).","journal-title":"JCI Insight"},{"key":"1229_CR191","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","volume":"32","author":"MA Travis","year":"2014","unstructured":"Travis, M. A. & Sheppard, D. TGF-\u03b2 activation and function in immunity. Annu. Rev. Immunol. 32, 51\u201382 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"1229_CR192","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069\u20131086 (2018).","journal-title":"Cancer Discov."},{"key":"1229_CR193","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130\u20133144 (2016).","journal-title":"J. Clin. Invest."},{"key":"1229_CR194","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong, E. A. et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129, 1039\u20131041 (2017).","journal-title":"Blood"},{"key":"1229_CR195","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","volume":"25","author":"A Heczey","year":"2017","unstructured":"Heczey, A. et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 25, 2214\u20132224 (2017).","journal-title":"Mol. Ther."},{"key":"1229_CR196","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq, S. et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat. Biotechnol. 36, 847\u2013856 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1229_CR197","doi-asserted-by":"publisher","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","volume":"23","author":"S Li","year":"2017","unstructured":"Li, S. et al. Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors. Clin. Cancer Res. 23, 6982\u20136992 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1229_CR198","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","volume":"51","author":"ME Prosser","year":"2012","unstructured":"Prosser, M. E., Brown, C. E., Shami, A. F., Forman, S. J. & Jensen, M. C. Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51, 263\u2013272 (2012).","journal-title":"Mol. Immunol."},{"key":"1229_CR199","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu, X. et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 76, 1578\u20131590 (2016).","journal-title":"Cancer Res."},{"key":"1229_CR200","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41551-024-01287-3","volume":"8","author":"SE James","year":"2024","unstructured":"James, S. E. et al. Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors. Nat. Biomed. Eng. 8, 1592\u20131614 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1229_CR201","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33793-w","volume":"13","author":"L Qin","year":"2022","unstructured":"Qin, L. et al. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70\u2013CD27 axis. Nat. Commun. 13, 6051 (2022).","journal-title":"Nat. Commun."},{"key":"1229_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp, L. J. et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci. Rep. 7, 737 (2017).","journal-title":"Sci. Rep."},{"key":"1229_CR203","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","volume":"30","author":"YH Lee","year":"2022","unstructured":"Lee, Y. H. et al. PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. Mol. Ther. 30, 579\u2013592 (2022).","journal-title":"Mol. Ther."},{"key":"1229_CR204","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","volume":"7","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CRISPR\u2013Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J. Immunother. Cancer 7, 304 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR205","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal, S. et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity 56, 2388\u20132407.e9 (2023).","journal-title":"Immunity"},{"key":"1229_CR206","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471\u2013482 (2019).","journal-title":"Cancer Cell"},{"key":"1229_CR207","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.tcb.2017.06.003","volume":"27","author":"CA Lyssiotis","year":"2017","unstructured":"Lyssiotis, C. A. & Kimmelman, A. C. Metabolic interactions in the tumor microenvironment. Trends Cell Biol. 27, 863\u2013875 (2017).","journal-title":"Trends Cell Biol."},{"key":"1229_CR208","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.3390\/cancers14215442","volume":"14","author":"J Rial Saborido","year":"2022","unstructured":"Rial Saborido, J., V\u00f6lkl, S., Aigner, M., Mackensen, A. & Mougiakakos, D. Role of CAR T cell metabolism for therapeutic efficacy. Cancers (Basel) 14, 5442 (2022).","journal-title":"Cancers (Basel)"},{"key":"1229_CR209","doi-asserted-by":"publisher","first-page":"100543","DOI":"10.1016\/j.xcrm.2022.100543","volume":"3","author":"J Foeng","year":"2022","unstructured":"Foeng, J., Comerford, I. & McColl, S. R. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep. Med. 3, 100543 (2022).","journal-title":"Cell Rep. Med."},{"key":"1229_CR210","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cancers11050674","volume":"11","author":"LM Whilding","year":"2019","unstructured":"Whilding, L. M. et al. CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel) 11, 674 (2019).","journal-title":"Cancers (Basel)"},{"key":"1229_CR211","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu, G. et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur. J. Immunol. 50, 712\u2013724 (2020).","journal-title":"Eur. J. Immunol."},{"key":"1229_CR212","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00262-024-03648-y","volume":"73","author":"Z Dai","year":"2024","unstructured":"Dai, Z. et al. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma. Cancer Immunol. Immunother. 73, 61 (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"1229_CR213","doi-asserted-by":"publisher","unstructured":"Johnston, A. C. et al. Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.12.13.571595 (2024).","DOI":"10.1101\/2023.12.13.571595"},{"key":"1229_CR214","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat. Rev. Clin. Oncol. 20, 49\u201362 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1229_CR215","doi-asserted-by":"publisher","DOI":"10.1038\/srep39833","volume":"7","author":"A Juillerat","year":"2017","unstructured":"Juillerat, A. et al. An oxygen sensitive self-decision making engineered CAR T-cell. Sci. Rep. 7, 39833 (2017).","journal-title":"Sci. Rep."},{"key":"1229_CR216","doi-asserted-by":"publisher","first-page":"eads3403","DOI":"10.1126\/sciadv.ads3403","volume":"11","author":"KC Vogt","year":"2025","unstructured":"Vogt, K. C. et al. Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Sci. Adv. 11, eads3403 (2025).","journal-title":"Sci. Adv."},{"key":"1229_CR217","doi-asserted-by":"publisher","first-page":"eadl4237","DOI":"10.1126\/science.adl4237","volume":"386","author":"MS Simic","year":"2024","unstructured":"Simic, M. S. et al. Programming tissue-sensing T cells that deliver therapies to the brain. Science 386, eadl4237 (2024).","journal-title":"Science"},{"key":"1229_CR218","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.cell.2024.01.035","volume":"187","author":"V Tieu","year":"2024","unstructured":"Tieu, V. et al. A versatile CRISPR\u2013Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell 187, 1278\u20131295.e20 (2024).","journal-title":"Cell"},{"key":"1229_CR219","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio, C. et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood 140, 619\u2013629 (2022).","journal-title":"Blood"},{"key":"1229_CR220","first-page":"65","volume":"67","author":"FG Herrera","year":"2017","unstructured":"Herrera, F. G., Bourhis, J. & Coukos, G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J. Clin. 67, 65\u201385 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"1229_CR221","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","volume":"7","author":"F Hauth","year":"2021","unstructured":"Hauth, F., Ho, A. Y., Ferrone, S. & Duda, D. G. Radiotherapy to enhance chimeric antigen receptor T-cell therapeutic efficacy in solid tumors: a narrative review. JAMA Oncol. 7, 1051\u20131059 (2021).","journal-title":"JAMA Oncol."},{"key":"1229_CR222","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodr\u00edguez-Ruiz","year":"2018","unstructured":"Rodr\u00edguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C. & Demaria, S. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 39, 644\u2013655 (2018).","journal-title":"Trends Immunol."},{"key":"1229_CR223","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera, F. G. et al. Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov. 12, 108\u2013133 (2022).","journal-title":"Cancer Discov."},{"key":"1229_CR224","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s43018-025-00905-6","volume":"6","author":"H Ni","year":"2025","unstructured":"Ni, H. et al. FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. Nat. Cancer 6, 460\u2013473 (2025).","journal-title":"Nat. Cancer"},{"key":"1229_CR225","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218632120","volume":"120","author":"D Mai","year":"2023","unstructured":"Mai, D. et al. Combined disruption of T cell inflammatory regulators regnase-1 and roquin-1 enhances antitumor activity of engineered human T cells. Proc. Natl Acad. Sci. USA 120, e2218632120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1229_CR226","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade2526","volume":"9","author":"U Uslu","year":"2023","unstructured":"Uslu, U. et al. Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma. Sci. Adv. 9, eade2526 (2023).","journal-title":"Sci. Adv."},{"key":"1229_CR227","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson, V. et al. The immune landscape of cancer. Immunity 48, 812\u2013830.e14 (2018).","journal-title":"Immunity"},{"key":"1229_CR228","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J. Hematol. Oncol. 17, 31 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1229_CR229","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02047-2","volume":"23","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. et al. Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond. Mol. Cancer 23, 131 (2024).","journal-title":"Mol. Cancer"},{"key":"1229_CR230","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1200\/JCO.2024.42.16_suppl.2664","volume":"42","author":"A Patnaik","year":"2024","unstructured":"Patnaik, A. et al. Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors. J. Clin. Oncol. 42, 2664\u20132664 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1229_CR231","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1016\/j.ymthe.2024.09.010","volume":"32","author":"X Wei","year":"2024","unstructured":"Wei, X. et al. A CD25\u2009\u00d7\u2009TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion. Mol. Ther. 32, 4075\u20134094 (2024).","journal-title":"Mol. Ther."},{"key":"1229_CR232","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000234","volume":"8","author":"T Yoshida","year":"2020","unstructured":"Yoshida, T. et al. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. J. Immunother. Cancer 8, e000234 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR233","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1182\/blood-2024-194162","volume":"144","author":"MB Geyer","year":"2024","unstructured":"Geyer, M. B. et al. CD371-targeted CAR T-cells secreting interleukin-18 exhibit robust expansion and disease clearance in patients with refractory acute myeloid leukemia. Blood 144, 2070 (2024).","journal-title":"Blood"},{"key":"1229_CR234","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat. Biotechnol. 42, 1693\u20131704 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1229_CR235","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/blood-2024-206439","volume":"144","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. IL-10 expressing CD19 CAR-T cells induce complete remission and improve long-term protection in relapsed or refractory B-cell hematological malignancies. Blood 144, 92 (2024).","journal-title":"Blood"},{"key":"1229_CR236","doi-asserted-by":"publisher","first-page":"1161067","DOI":"10.3389\/fimmu.2023.1161067","volume":"14","author":"V Carlini","year":"2023","unstructured":"Carlini, V. et al. The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. Front. Immunol. 14, 1161067 (2023).","journal-title":"Front. Immunol."},{"key":"1229_CR237","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-023-00625-0","volume":"10","author":"W Lei","year":"2024","unstructured":"Lei, W. et al. Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discov. 10, 5 (2024).","journal-title":"Cell Discov."},{"key":"1229_CR238","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1200\/JCO.23.02786","volume":"42","author":"MD Jain","year":"2024","unstructured":"Jain, M. D. et al. Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium. J. Clin. Oncol. 42, 3581\u20133592 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1229_CR239","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","volume":"17","author":"P Sesques","year":"2024","unstructured":"Sesques, P. et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J. Hematol. Oncol. 17, 61 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1229_CR240","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637, 940\u2013946 (2025).","journal-title":"Nature"},{"key":"1229_CR241","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","volume":"159","author":"RE O\u2019Cearbhaill","year":"2020","unstructured":"O\u2019Cearbhaill, R. E. et al. A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC). Gynecol. Oncol. 159, 42 (2020).","journal-title":"Gynecol. Oncol."},{"key":"1229_CR242","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski, M., Hombach, A. A. & Abken, H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257, 83\u201390 (2014).","journal-title":"Immunol. Rev."},{"key":"1229_CR243","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski, M., Kopecky, C., Hombach, A. A. & Abken, H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71, 5697\u20135706 (2011).","journal-title":"Cancer Res."},{"key":"1229_CR244","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi, G. et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat. Commun. 12, 444 (2021).","journal-title":"Nat. Commun."},{"key":"1229_CR245","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine, B. L., Miskin, J., Wonnacott, K. & Keir, C. Global manufacturing of CAR T cell therapy. Mol. Ther.-Methods Clin. Dev. 4, 92\u2013101 (2017).","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"1229_CR246","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi, S. et al. Rapid manufacturing of non-activated potent CAR T cells. Nat. Biomed. Eng. 6, 118\u2013128 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1229_CR247","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson, M. J. et al. A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 13, 1982\u20131997 (2023).","journal-title":"Cancer Discov."},{"key":"1229_CR248","doi-asserted-by":"publisher","first-page":"215710","DOI":"10.1016\/j.canlet.2022.215710","volume":"538","author":"L Shen","year":"2022","unstructured":"Shen, L. et al. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity. Cancer Lett. 538, 215710 (2022).","journal-title":"Cancer Lett."},{"key":"1229_CR249","doi-asserted-by":"publisher","first-page":"101249","DOI":"10.1016\/j.omtm.2024.101249","volume":"32","author":"D Cappabianca","year":"2024","unstructured":"Cappabianca, D. et al. Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence. Mol. Ther. Methods Clin. Dev. 32, 101249 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1229_CR250","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s42255-020-0256-z","volume":"2","author":"RI Klein Geltink","year":"2020","unstructured":"Klein Geltink, R. I. et al. Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy. Nat. Metab. 2, 703\u2013716 (2020).","journal-title":"Nat. Metab."},{"key":"1229_CR251","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.cmet.2024.12.007","volume":"37","author":"AT Frisch","year":"2025","unstructured":"Frisch, A. T. et al. Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy. Cell Metab. 37, 870\u2013885 (2025).","journal-title":"Cell Metab."},{"key":"1229_CR252","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cmet.2023.02.013","volume":"35","author":"CB Nava Lauson","year":"2023","unstructured":"Nava Lauson, C. B. et al. Linoleic acid potentiates CD8+ T cell metabolic fitness and antitumor immunity. Cell Metab. 35, 633\u2013650.e9 (2023).","journal-title":"Cell Metab."},{"key":"1229_CR253","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24331-1","volume":"12","author":"M Luu","year":"2021","unstructured":"Luu, M. et al. Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer. Nat. Commun. 12, 4077 (2021).","journal-title":"Nat. Commun."},{"key":"1229_CR254","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"1229_CR255","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s42255-024-01034-7","volume":"6","author":"A Lakhani","year":"2024","unstructured":"Lakhani, A. et al. Extracellular domains of CARs reprogramme T cell metabolism without antigen stimulation. Nat. Metab. 6, 1143\u20131160 (2024).","journal-title":"Nat. Metab."},{"key":"1229_CR256","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.MCT-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina, A. & Maher, J. Strategies to address chimeric antigen receptor tonic signaling. Mol. Cancer Ther. 17, 1795\u20131815 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"1229_CR257","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","volume":"27","author":"N Singh","year":"2021","unstructured":"Singh, N. et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat. Med. 27, 842\u2013850 (2021).","journal-title":"Nat. Med."},{"key":"1229_CR258","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44, 380\u2013390 (2016).","journal-title":"Immunity"},{"key":"1229_CR259","doi-asserted-by":"publisher","first-page":"109593","DOI":"10.1016\/j.intimp.2022.109593","volume":"114","author":"AS Razavi","year":"2023","unstructured":"Razavi, A. S., Loskog, A., Razi, S. & Rezaei, N. The signaling and the metabolic differences of various CAR T cell designs. Int. Immunopharmacol. 114, 109593 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"1229_CR260","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52666-y","volume":"15","author":"JA Guerrero","year":"2024","unstructured":"Guerrero, J. A. et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat. Commun. 15, 8658 (2024).","journal-title":"Nat. Commun."},{"key":"1229_CR261","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ymthe.2024.05.006","volume":"32","author":"Y Shi","year":"2024","unstructured":"Shi, Y. et al. GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol. Ther. 32, 2393\u20132405 (2024).","journal-title":"Mol. Ther."},{"key":"1229_CR262","doi-asserted-by":"publisher","unstructured":"Valenti\u0107, B. et al. The glucose transporter 5 enhances CAR-T cell metabolic function and anti-tumour durability. Preprint at Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-4342820\/v1 (2024).","DOI":"10.21203\/rs.3.rs-4342820\/v1"},{"key":"1229_CR263","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1182\/bloodadvances.2022008272","volume":"7","author":"S Panetti","year":"2023","unstructured":"Panetti, S. et al. Engineering amino acid uptake or catabolism promotes CAR T-cell adaption to the tumor environment. Blood Adv. 7, 1754\u20131761 (2023).","journal-title":"Blood Adv."},{"key":"1229_CR264","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41586-024-08071-y","volume":"635","author":"SM Hwang","year":"2024","unstructured":"Hwang, S. M. et al. Transgelin 2 guards T cell lipid metabolism and antitumour function. Nature 635, 1010\u20131018 (2024).","journal-title":"Nature"},{"key":"1229_CR265","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.immuni.2021.05.003","volume":"54","author":"S Xu","year":"2021","unstructured":"Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity 54, 1561\u20131577.e7 (2021).","journal-title":"Immunity"},{"key":"1229_CR266","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","volume":"25","author":"RM Peralta","year":"2024","unstructured":"Peralta, R. M. et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat. Immunol. 25, 2297\u20132307 (2024).","journal-title":"Nat. Immunol."},{"key":"1229_CR267","doi-asserted-by":"publisher","first-page":"108500","DOI":"10.1016\/j.celrep.2020.108500","volume":"33","author":"WJ Quinn","year":"2020","unstructured":"Quinn, W. J. et al. Lactate limits T cell proliferation via the NAD(H) redox state. Cell Rep. 33, 108500 (2020).","journal-title":"Cell Rep."},{"key":"1229_CR268","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.abj5104","volume":"377","author":"G Notarangelo","year":"2022","unstructured":"Notarangelo, G. et al. Oncometabolite d-2HG alters T cell metabolism to impair CD8+ T cell function. Science 377, 1519\u20131529 (2022).","journal-title":"Science"},{"key":"1229_CR269","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cmet.2023.04.017","volume":"35","author":"J Cheng","year":"2023","unstructured":"Cheng, J. et al. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment. Cell Metab. 35, 961\u2013978.e10 (2023).","journal-title":"Cell Metab."},{"key":"1229_CR270","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4049\/jimmunol.1401710","volume":"196","author":"MA Ligtenberg","year":"2016","unstructured":"Ligtenberg, M. A. et al. Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity. J. Immunol. 196, 759\u2013766 (2016).","journal-title":"J. Immunol."},{"key":"1229_CR271","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122299","volume":"3","author":"K Pilipow","year":"2018","unstructured":"Pilipow, K. et al. Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity. JCI Insight 3, e122299 (2018).","journal-title":"JCI Insight"},{"key":"1229_CR272","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1126\/science.adl4100","volume":"387","author":"SK Varanasi","year":"2025","unstructured":"Varanasi, S. K. et al. Bile acid synthesis impedes tumor-specific T cell responses during liver cancer. Science 387, 192\u2013201 (2025).","journal-title":"Science"},{"key":"1229_CR273","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/blood.2019004500","volume":"136","author":"L Fultang","year":"2020","unstructured":"Fultang, L. et al. Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood 136, 1155\u20131160 (2020).","journal-title":"Blood"},{"key":"1229_CR274","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","volume":"5","author":"SM Steggerda","year":"2017","unstructured":"Steggerda, S. M. et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J. Immunother. Cancer 5, 101 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR275","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.132975","volume":"4","author":"AA Mart\u00ed i L\u00edndez","year":"2019","unstructured":"Mart\u00ed i L\u00edndez, A. A. et al. Mitochondrial arginase-2 is a cell-autonomous regulator of CD8+ T cell function and antitumor efficacy. JCI Insight 4, e132975 (2019).","journal-title":"JCI Insight"},{"key":"1229_CR276","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya, S. et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905\u20133916 (2015).","journal-title":"Blood"},{"key":"1229_CR277","doi-asserted-by":"publisher","first-page":"679517","DOI":"10.3389\/fonc.2021.679517","volume":"11","author":"P Li","year":"2021","unstructured":"Li, P. et al. IDO inhibition facilitates antitumor immunity of V\u03b39V\u03b42 T cells in triple-negative breast cancer. Front. Oncol. 11, 679517 (2021).","journal-title":"Front. Oncol."},{"key":"1229_CR278","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-018-0600-x","volume":"11","author":"Q Huang","year":"2018","unstructured":"Huang, Q. et al. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. J. Hematol. Oncol. 11, 58 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"1229_CR279","doi-asserted-by":"publisher","first-page":"661357","DOI":"10.3389\/fimmu.2021.661357","volume":"12","author":"J Shao","year":"2021","unstructured":"Shao, J. et al. Indoleamine 2,3-dioxygenase 1 inhibitor-loaded nanosheets enhance CAR-T cell function in esophageal squamous cell carcinoma. Front. Immunol. 12, 661357 (2021).","journal-title":"Front. Immunol."},{"key":"1229_CR280","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye, L. et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab. 34, 595\u2013614.e14 (2022).","journal-title":"Cell Metab."},{"key":"1229_CR281","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s42255-023-00855-2","volume":"5","author":"E Minogue","year":"2023","unstructured":"Minogue, E. et al. Glutarate regulates T cell metabolism and anti-tumour immunity. Nat. Metab. 5, 1747\u20131764 (2023).","journal-title":"Nat. Metab."},{"key":"1229_CR282","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan, J. D. et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 629, 201\u2013210 (2024).","journal-title":"Nature"},{"key":"1229_CR283","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006522","volume":"11","author":"K Lontos","year":"2023","unstructured":"Lontos, K. et al. Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors. J. Immunother. Cancer 11, e006522 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1229_CR284","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A. E. et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218 (2024).","journal-title":"Nature"},{"key":"1229_CR285","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.177141","volume":"9","author":"R Hatae","year":"2024","unstructured":"Hatae, R. et al. Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment. JCI Insight 9, e177141 (2024).","journal-title":"JCI Insight"}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-025-01229-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-025-01229-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-025-01229-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:03:33Z","timestamp":1772118213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-025-01229-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":285,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1229"],"URL":"https:\/\/doi.org\/10.1038\/s41577-025-01229-3","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"10 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H.J. is an inventor of patents and\/or patent applications licensed to Novartis Institutes of Biomedical Research and receives licence revenue from such licences; is an inventor on patents and\/or patent applications licensed to Kite Pharma, Capstan Therapeutics, Dispatch Therapeutics and BlueWhale Bio; and is a member of the scientific advisory boards of AC Immune, BluesphereBio, BlueWhale Bio, Cabaletta, Carisma, Cartography, Cellares, Celldex, Decheng, Replay Bio, Verismo and WIRB-Copernicus. Y.F. is a co-founder of Radix Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}